Bayer Reaches $173 Million Settlement with Takeda Over Adynovate Patent

Takeda Pharmaceutical subsidiary Baxalta and Bayer have hashed out a settlement that will dismiss a 2019 jury verdict that ordered Baxalta to pay $173 million for infringing on Bayer’s patents for the hemophilia A drug Adynovate, with Bayer agreeing not to pursue the money it is owed.

Takeda had appealed the damages it was required to pay by the jury to no avail, with the U.S. Court of Appeals for the Federal Circuit rejecting its appeal in March. But its ongoing fight against the verdict will come to an end now that Baxalta, Bayer and Nektar Therapeutics, which collaborated with Baxalta on Adynovate (antihemophilic factor — recombinant — PEGylated) and also with Bayer on its version of the drug, have reached an agreement that ends the litigation.

Under the terms of the settlement, the companies will pay their own respective legal fees and Bayer will not make any claims for the $173 million payment. The financial terms of the deal between the drugmakers were not disclosed.